Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

VOLUNTARY ANNOUNCEMENT
CAPITAL INCREASE IN A MEDICAL IMAGING ARTIFICIAL INTELLIGENCE COMPANY

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Jiangxi Rimag Group Co., Ltd. (the "**Company**" or "**Jiangxi Rimag**"), together with its subsidiaries collectively referred to as (the "**Group**") on a voluntary basis.

The Board is pleased to announce that on October 29, 2025 (the "**Signing Date**"), the Company entered into a Capital Increase and Subscription Agreement (the "**Agreement**") with Shanghai Medical Image Insights Intelligent Technology Co., Ltd. (上海影禾醫脈智能科技有限公司) ("**Medical Image Insights**") and its related parties, pursuant to which, the Company subscribed for the newly increased registered capital of Medical Image Insights at a total consideration of approximately RMB100 million. Upon completion of the transaction, the Company's aggregate shareholding interest in Medical Image Insights will be further enhanced.

The Board is of the view that artificial intelligence in medical imaging, as the core development direction of the future medical technology field, is entering into a golden age of rapidly expanding market demand. With the acceleration of digital transformation in healthcare, the clinical demand for precise and efficient imaging diagnostics is becoming increasingly urgent. The market scope in this field will continue to expand, demonstrating long-term growth potential. Medical Image Insights's core business covers the operation of a full-process intelligent service platform for medical imaging, AI-assisted diagnosis technology, and digital imaging solutions, and its technical capabilities and product implementation are highly complementary to the Company's existing imaging service ecosystem, enabling the deep integration of resources between the two parties.

The Capital Increase and increase in shareholding ratio are important measures for the Company to implement the AI three-in-one strategy for medical imaging (medical imaging data + AI foundation model + imaging center scenario), which is highly consistent with its long-term development plan to deepen the medical imaging field. By strengthening the capital connection with Medical Image Insights, the development mechanism of "incubating twins" between the two parties will be further activated. The high-quality data resources accumulated by the Company's long-term deep cultivation of the informatization of the imaging center and the AI technology iteration of Medical Image Insights will form a two-way empowerment closed loop. In essence, we will build a healthy interactive development pattern from informatization to data, and then from data to AI capabilities.

For strategic benefits, the Investment will bring improvements to the Company in various aspects: in terms of industrial chain layout, with the help of Medical Image Insights's technological advantages, the Group will further improve its business chain, accelerate the transition towards a data-driven service model, and promote its core commercial competitiveness within the industry; in terms of service quality, relying on the technical achievements of Medical Image Insights, the diagnostic accuracy and efficiency of the imaging centers and cooperative medical institutions under the Group will be significantly improved to better meet clinical needs; in the market competition, the Investment will help the Group to occupy a more favorable position in the rapidly developing imaging AI field, seize the development opportunities in the industry and achieve sustained business growth.

It is expected that the Investment will strengthen the Group's layout in the medical imaging industry chain, improve the accuracy and efficiency of the Group's imaging diagnosis services, empower its existing businesses, obtain a strategic fulcrum in the rapidly growing imaging AI field, and enhance the Group's innovation capabilities and competitive advantages in smart medical solutions. It will also consolidate the Company's leadership in medical imaging AI field in China by building a closed-loop "data + algorithm + scenario" chain.

The Board considers that the terms of the Agreement are fair and reasonable and in the interests of the Company and its Shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
江西一脈陽光集團股份有限公司
Mr. CHEN Zhaoyang
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, October 30, 2025

As of the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.